Total number of patients (%) | ||
---|---|---|
Gender | ||
Male | 21 (75.0%) | |
Female | 7 (25.0%) | |
Median Age (range) in years | 63 (48–91) | |
Median KPS (range) in % | 80 (60–100%) | |
Primary Tumor Site | ||
NSCLC | 13 (46.4%) | |
SCLC | 5 (17.9%) | |
CRC | 1 (3.6%) | |
HCC | 1 (3.6%) | |
Breast cancer | 1 (3.6%) | |
Melanoma | 1 (3.6%) | |
RCC | 2 (7.1%) | |
Other | 4 (14.3%) | |
Oligometastatic | 21 (75%) | |
Oligoprogressive | 7 (25%) | |
Total no of metastatic sites | ||
0 | 17 (60.7%) | |
1 | 2 (7.1%) | |
2 | 2 (7.1%) | |
3 | 1 (3.6%) | |
> 5 | 6 (21.4%) | |
Laterality | ||
Right | 14 (50.0%) | |
Left | 14 (50.0%) | |
Metastasis status | ||
Synchronous | 10 (35.7%) | |
Metachronous | 18 (64.3%) | |
Median time from primary diagnosis to adrenal gland metastasis (range) in months | 14 (0–102) | |
Homogeneity distribution (%) | ||
Yes | 26 (92.9%) | |
No | 2 (7.1%) | |
Forced dose restriction (%) | ||
Yes | 14 (50.0%) | |
No | 14 (50.0%) | |
RT Technique | ||
3D conformal | 4 (14.3%) | |
Helical IMRT (Tomotherapy) | 13 (46.4%) | |
VMAT | 11 (39.3%) | |
FFF photons utilized | ||
Yes | 18 (64.3%) | |
No | 10 (35.7%) | |
Concurrent systemic therapy | ||
No | 19 (67.9%) | |
Yes | 9 (32.1%) | |
Chemotherapy | 6 (66.7%) | |
Targeted therapy | 2 (22.2%) | |
Immunotherapy | 1 (11.1%) | |
Mean | Median (range) | |
Total dose (Gy) | 47.3 | 50 (30–54) |
Fractions (n) | 9 | 10 (3–12) |
Single dose (Gy) | 5.6 | 5 (4–18) |
BED10 (Gy) | 73.5 | 75 (57.6–151.2) |
Prescribed isodose line (%) | 89 | 90 (80–90) |
Median GTV volume (range) in cm3 | 27 | 42 (3–233) |
Median PTV volume (range) in cm3 | 111 | 96 (16–346) |